Stone X Group Inc. Pro Qr Therapeutics N.V. Transaction History
Stone X Group Inc.
- $2.29 Trillion
- Q3 2025
Shares
1 transactions
Others Institutions Holding PRQR
# of Institutions
65Shares Held
38.3MCall Options Held
0Put Options Held
0-
Adage Capital Partners Gp, L.L.C. Boston, MA6.25MShares$13.7 Million0.02% of portfolio
-
Privium Fund Management B.V.5MShares$10.9 Million1.92% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.6MShares$7.88 Million0.88% of portfolio
-
Morgan Stanley New York, NY2.9MShares$6.35 Million0.0% of portfolio
-
Abrdn PLC2.3MShares$5.03 Million0.01% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $156M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...